Literature DB >> 7056276

Protein binding of piretanide in normal and uraemic serum.

H L Elliott, A F Ansari, B C Campbell, J R Lawrence.   

Abstract

The protein binding of piretanide was assessed by continuous ultrafiltration of sera from six normal subjects and seven uraemic subjects (samples taken immediately pre-dialysis). Throughout the range of piretanide concentrations studied (0.5-4.5mM), the mean protein binding for uraemic serum was less than that for normal serum. This difference was significant (p less than 0.05) at piretanide concentrations of 1.5 mM and above, but not at 1mM where mean protein binding for uraemic serum was 88.1% compared to 94.2% for normal serum. Analysis of piretanide protein binding characteristics using the Rosenthal plot showed no significant differences between uraemic and normal serum with respect to primary or secondary binding sites. Parallel assessment by the Scatchard method suggests, as expected, that albumin is the principle protein moiety responsible for binding piretanide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7056276     DOI: 10.1007/bf00637619

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  A graphic method for the determination and presentation of binding parameters in a complex system.

Authors:  H E Rosenthal
Journal:  Anal Biochem       Date:  1967-09       Impact factor: 3.365

2.  Distribution, elimination and natriuretic effect of furosemide in patients with severe arterial hypertension.

Authors:  F Andreasen; O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

3.  Decreased drug binding by serum albumin during renal failure.

Authors:  D S Campion
Journal:  Toxicol Appl Pharmacol       Date:  1973-07       Impact factor: 4.219

4.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

5.  Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure.

Authors:  F Andreasen; P Jakobsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-07

6.  Measurement of drug displacement by continuous ultrafiltration.

Authors:  D S Campion; R Olsen
Journal:  J Pharm Sci       Date:  1974-02       Impact factor: 3.534

7.  The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.

Authors:  D W Shoeman; D L Azarnoff
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

8.  Kinetic and dynamic comparison of piretanide and furosemide.

Authors:  J R Lawrence; A F Ansari; H L Elliott; D J Sumner; G F Brunton; B Whiting; R Whitesmith
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

9.  Effects of piretanide, bumetanide and frusemide on electrolyte and urate excretion in normal subjects.

Authors:  C J Roberts; M Homeida; F Roberts; W Bogie
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

10.  Activity of a new high efficiency diuretic in man: piretanide (HOE 118).

Authors:  N Pozet; A Hadj-Aissa; M Pellet; J Traeger
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

View more
  4 in total

Review 1.  Clinical pharmacokinetics of some newer diuretics.

Authors:  B Beermann; M Grind
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 2.  Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

3.  Pharmacokinetics of high doses of piretanide in moderate to severe renal failure.

Authors:  C Marone; F C Reubi; M Perisic; W Lahn
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Pharmacokinetics of the loop diuretic piretanide in renal failure.

Authors:  U Walter; A Röckel; W Lahn; A Heidland; W Heptner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.